Medical Condition News

RSS

Recent data from CNSBio's Phase IIa CNSB015 trial to be presented at the Neuropathic Pain conference

CNSBio Inc. will present recent Phase IIa proof-of-concept clinical trial data for CNSB015, an orally administered potassium channel modulator used in combination with opioids for the treatment of neuropathic pain, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain on November 20-21, 2009 in San Francisco, CA.

18 Nov 2009

IBM scientists work with Rizzoli Orthopedic Institute to use BioMIMS to treat genetic skeletal diseases

IBM ( IBM) announced today that its Research scientists are working with the Rizzoli Orthopedic Institute, in Bologna, Italy, to use information technology to better address treatment and research for rare genetic skeletal diseases.

18 Nov 2009

Way to capture tumor cells in the bloodstream discovered

A team led by University of Arkansas for Medical Sciences (UAMS) researchers on the cutting edge of nanotechnology has found a way to capture tumor cells in the bloodstream that could dramatically improve earlier cancer diagnosis and prevent deadly metastasis.

18 Nov 2009

Enzo Biochem to market GeneNews’ ColonSentry in New York and New Jersey

Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has entered into an agreement with GeneNews (TSX: GEN), of Toronto, Canada, for exclusive rights to market GeneNews’ ColonSentry™, a proprietary blood test for colorectal cancer, in the states of New York and New Jersey.

18 Nov 2009

Johns Hopkins University to create a Human Proteome Chip using Arrayit's technology

Arrayit Corporation announced today that the new High Throughput Biology Center at Johns Hopkins University School of Medicine in Baltimore Maryland purchased Arrayit's proprietary technology to create a Human Proteome Chip to discover biomarkers for autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, autoimmune hepatitis (first identified by Dr. Zhu), lupus, and others.

18 Nov 2009

Researchers identify new way to capture tumor cells in bloodstream; findings can improve early cancer diagnosis

Jin-Woo Kim, a biomedical engineering researcher at the University of Arkansas, is part of a cutting-edge nanotechnology research group that has discovered a way to capture tumor cells in the bloodstream. The work could dramatically improve early cancer diagnosis and prevent deadly metastasis.

18 Nov 2009

Canadian comedian helps raise awareness about COPD

COPD is no joke to Canadian comedian Mary Walsh. "It's shocking that so few Canadians know about COPD considering it's the fourth leading cause of death in this country," says Mary Walsh, spokesperson for The Canadian Lung Association.

18 Nov 2009

First proclamation in support of Mental Health initiative in the state of Tennessee issued

On November 9, 2009, Honorable Speaker of the Senate Ron Ramsey, and Honorable Senator Mark Norris issued the first proclamation in support of a Mental Health initiative in the state of Tennessee. This is a major breakthrough to benefit people living with bipolar disorder in the State of Tennessee, and support The Brilliance in Bipolar Initiative.

18 Nov 2009

MU occupational therapy professor says recovery from brain injuries can last a lifetime

Until recently, scientists believed that, following a stroke, a patient had about six months to regain any lost function. After that, patients would be forced to compensate for the lost function by focusing on their remaining abilities. Although this belief has been refuted, a University of Missouri occupational therapy professor believes that the current health system is still not giving patients enough time to recover and underestimating what the human brain can do given the right conditions.

18 Nov 2009

Phase 2/3 study results of Genzyme's APB announced

Genzyme Corporation today reported results of a phase 2/3 study of its advanced phosphate binder (APB). The trial met its primary endpoint, which was to show that the APB lowered phosphate levels effectively compared to placebo. However, the APB did not show a significant improvement in phosphate lowering compared to Genzyme’s Renvela® (sevelamer carbonate).

18 Nov 2009

Study: Larger dose of ARBs is more effective in heart failure patients

A larger dose of angiotensin receptor blockers (ARBs) is more effective than a smaller dose in heart failure patients, researchers said at the American Heart Association's Scientific Sessions 2009.

18 Nov 2009

Gene that tells embryonic stem cells when to stop producing neurons identified

Researchers from North Carolina State University have identified a gene that tells embryonic stem cells in the brain when to stop producing nerve cells called neurons. The research is a significant advance in understanding the development of the nervous system, which is essential to addressing conditions such as Parkinson's disease, Alzheimer's disease and other neurological disorders.

18 Nov 2009

A fact-based media briefing on bipolar disorder in Nova Scotia

An estimated 26,000 Nova Scotians live with bipolar disorder. Often stigmatized in popular culture, the experience of bipolar disorder varies from one person to the next and almost always has a drastic impact on how individuals think, behave and function.

18 Nov 2009

Pluristem’s PLX-PAD holds promise for critical limb ischemia

Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company’s leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).

18 Nov 2009

The Center for Modeling Optimal Outcomes discovers causal path of autism

During its research into the application of neuroscience in business, a New Jersey based think tank, The Center for Modeling Optimal Outcomes®, LLC (The Center) made an inadvertent and amazing discovery.

18 Nov 2009

Cancer-fighting protein successfully placed directly into solid tumors and turned on

Experiments at the Pioneer Valley Life Sciences Institute (PVLSI) at Baystate Medical Center in Springfield, Mass., reported in a recent British Journal of Cancer, confirm that University of Massachusetts Amherst chemical engineer Neil Forbes' delivery and trigger system has for the first time successfully placed TRAIL, a cancer-fighting protein, directly into solid tumors and on cue, turned it on. The treatment improved the 30-day survival time of mice with mammary tumors from 0 to 100 percent.

18 Nov 2009

Findings of Merck's anacetrapib phase IIb study presented at the AHA sessions

In a phase IIb study in 589 patients with primary hypercholesterolemia or mixed hyperlipidemia treated with anacetrapib as monotherapy or co-administered with atorvastatin, there were persistent lipid effects in the higher dose arms in both the monotherapy and co-administration treatment groups eight weeks after stopping active therapy with anacetrapib.

18 Nov 2009

Cardiologists detect atherosclerosis in ancient Egyptian mummies

A cardiologist at Saint Luke's Mid America Heart Institute and his research colleagues from Cairo, Milwaukee, and Mission Viejo, Calif., have detected hardening of the arteries in 3,500-year-old Egyptian mummies, indicating that heart disease is not just a condition found in modern humans.

18 Nov 2009

Ambrisentan improves health and exercise capacity of PAH patients, find researchers

In one of the few studies of the long-term effects of medication in the treatment of pulmonary arterial hypertension (PAH) disease, a team of researchers found the health and exercise capacity of PAH patients improved after two years of treatment with ambrisentan, according to a study published in the current edition of the Journal of the American College of Cardiology.

18 Nov 2009

CRESTOR reduces major cardiovascular events in women by 46%

A new analysis of the JUPITER trial, released today at the American Heart Association meeting in Orlando, Florida, demonstrates that CRESTOR (rosuvastatin calcium) 20mg reduced first major cardiovascular events by 46%.

18 Nov 2009

Medical Condition News

Recent data from CNSBio's Phase IIa CNSB015 trial to be presented at the Neuropathic Pain conference

IBM scientists work with Rizzoli Orthopedic Institute to use BioMIMS to treat genetic skeletal diseases

Way to capture tumor cells in the bloodstream discovered

Enzo Biochem to market GeneNews’ ColonSentry in New York and New Jersey

Johns Hopkins University to create a Human Proteome Chip using Arrayit's technology

Researchers identify new way to capture tumor cells in bloodstream; findings can improve early cancer diagnosis

Canadian comedian helps raise awareness about COPD

First proclamation in support of Mental Health initiative in the state of Tennessee issued

MU occupational therapy professor says recovery from brain injuries can last a lifetime

Phase 2/3 study results of Genzyme's APB announced

Study: Larger dose of ARBs is more effective in heart failure patients

Gene that tells embryonic stem cells when to stop producing neurons identified

A fact-based media briefing on bipolar disorder in Nova Scotia

Pluristem’s PLX-PAD holds promise for critical limb ischemia

The Center for Modeling Optimal Outcomes discovers causal path of autism

Cancer-fighting protein successfully placed directly into solid tumors and turned on

Findings of Merck's anacetrapib phase IIb study presented at the AHA sessions

Cardiologists detect atherosclerosis in ancient Egyptian mummies

Ambrisentan improves health and exercise capacity of PAH patients, find researchers

CRESTOR reduces major cardiovascular events in women by 46%

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News